Tonix Pharmaceuticals to sell 2.18 million units in public offering

Roth, National Securities to sell units at an expected price of $5.50

By Devika Patel

Knoxville, Tenn., Aug. 8 - Tonix Pharmaceuticals Holding Corp. plans to sell 2,181,819 units in its public sale, with 327,273 additional units as part of a greenshoe, according to a Form S-1/A filed Thursday with the Securities and Exchange Commission. The deal was announced May 10.

The company will sell the units of one common share and one five-year warrant at an expected price of $5.50 per unit.

Roth Capital Partners, National Securities Corp. and Dawson James Securities, Inc. are the bookrunners.

Proceeds will be used for the clinical development of TNX-102 SL, including a phase 2b clinical trial, and general corporate purposes, including working capital and operational purposes, including pre-clinical development.

Tonix is a specialty pharmaceutical company based in Zurich.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.